- Home
- PSHG vs LSTA Comparison
PSHG vs LSTA Comparison
Compare PSHG & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | LSTA |
|---|---|---|
| Founded | 2010 | 1980 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 28.9M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PSHG | LSTA |
|---|---|---|
| Price | $1.72 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 63.2K | ★ 105.0K |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.62 | $1.81 |
| 52 Week High | $2.58 | $5.07 |
Technical Indicators
Market Signals| Indicator | PSHG | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 51.45 |
| Support Level | $1.62 | $3.06 |
| Resistance Level | $2.10 | $3.67 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.66 | 24.32 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.